Nonalcoholic fatty liver disease (NAFLD) patients who are scheduled for liver biopsy for the differential diagnosis of NASH and/or NAFLD patients who are scheduled for the MR elastography (MRE) and MRI-proton density fat friction (MRI-PDFF).
Without a history of alcohol use, which lead to alcoholic hepatic involvement (pure alcohol below 30 g/day for male, 20 g/day for female).
You may not be if
Patients with endocrine disorder (hypopituitarism, growth hormone deficiency, hyperthyroidism etc.), serious nutrition disorder, and drug-induced hepatic involvement (steroid, tamoxifen, valproic acid, amiodarone etc.), which may lead to the steatosis
Hepatitis B, Hepatitis C and HIV patients
Primary biliary cholangitis, Primary sclerosing cholangitis, and Autoimmune hepatitis patients
Wilson's disease, α1-antitrypsin deficiency, and hemochromatosis patients
Malignant liver tumor, common bile duct stone, and jaundice patients
Patients after jejunoileal bypass surgery or massive intestinal resection surgery
Patients whose treatment changes during the period between imaging examination and liver biopsy, including medications such as antidiabetic drugs and other treatments which may change the fat deposition or inflammation of liver.
Clareo Health | Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study
